Featured

Status

Health Topics

Any Category
Diseases
Clear Filters

Search Clinical Trials

215 Results
Not Yet Recruiting
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
The study team will collect up to 18 teaspoons of patients' blood. This will be used this blood to grow T cells. The study team then grows the T cells …
Baylor Role: Lead Sponsor
Not Yet Recruiting
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
To make the T cells, the investigators will take the patient's blood and stimulate it with growth factors to make T cells grow. Investigators use a retrovirus to insert HER …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer
Once participants' eligibility has been confirmed, and participants have been registered in the study, the participants will receive immunotherapy treatment with Atezolizumab, followed by administration of CAPEOX chemotherapy for a …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States
The investigators' hypothesis is that the artificial intelligence (AI) mobile, high-resolution microendoscope (mHRME) will increase the accuracy of Lugol's chromoendoscopy (LCE) in endoscopic cancer detection in low- and middle-income countries …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
This is a dose escalation study. This means that at the beginning, patients will be started on the lowest dose (1 of 4 different levels) of C7R.CD30.CAR-EBVST cells. Once the …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Novel Rigidizing Overtube in Colonic Endoscopic Submucosal Dissection
Endoscopic submucosal dissection (ESD) is preferred resection method for advanced colonic polyp due to its higher rates of en bloc and R0 resection which lead to higher curative resection rate.1 …
Baylor Role: Lead Sponsor
Recruiting
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
First, patients provide blood for us to make TAA-specific cytotoxic T cells in the lab. The amount of blood to be drawn will be less based on the child's weight …
Baylor Role: Lead Sponsor
Not Yet Recruiting
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)
Patients will be enrolled to this study in two treatment groups: C7R-EBVSTs without lymphodepletion (Group A) and C7R-EBVSTs with lymphodepletion (Group B). The investigators will enroll patients into group B …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies
This study will examine both Human papillomavirus (HPV) vaccine effectiveness and Primary high-risk HPV PHS screening triage strategies in women living with HIV (WLHIV) by partnering with the Pediatric HIV/AIDs …
Baylor Role: Collaborator